ImmunoSep Study: Precision Immunotherapy Shows Promise in Sepsis Treatment

Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection, affects millions annually. The varied immune responses in sepsis patients have hindered the success of previous immunotherapy trials.

A new multicenter randomized clinical trial, the ImmunoSep study, investigated whether a precision immunotherapy strategy tailored to specific immune dysfunction patterns could improve outcomes in sepsis patients.

Tailoring Treatment: Identifying Immune Dysfunction Patterns

The ImmunoSep trial focused on two distinct patterns of immune dysregulation:

• Macrophage activation–like syndrome: Characterized as a hyperinflammatory state.
• Sepsis-induced immunoparalysis: Defined as a hypoinflammatory state.

Patients were classified based on blood ferritin levels and human leukocyte antigen DR receptors on CD45/CD14 monocytes. Ferritin levels above 4420 ng/mL indicated macrophage activation–like syndrome. Conversely, lower ferritin levels combined with fewer than 5000 HLA-DR receptors indicated sepsis-induced immunoparalysis. This precise stratification was crucial for the study's personalized approach.

ImmunoSep: A Precision-Guided Trial Design

This randomized, double-anonymized, placebo-controlled trial spanned 33 sites across 6 countries. Adult participants with sepsis originating from various sources—community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, or primary bacteremia—were enrolled.

Out of 672 screened patients, 276 were included in the primary analysis, with a mean age of 70 years and 33.7% female participants.

Patients were randomized to receive either standard care plus precision immunotherapy or standard care plus placebo for up to 15 days.

Specifically, patients diagnosed with macrophage activation–like syndrome received intravenous anakinra (an interleukin 1 receptor antagonist). Those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma.

Key Findings: Significant Organ Dysfunction Improvement

Primary Outcome: SOFA Score Reduction

The trial's primary endpoint was defined as a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9.

Results indicated a significant improvement in organ dysfunction within the precision immunotherapy group:

• Precision Immunotherapy Group: 46 of 131 patients (35.1%) achieved the primary endpoint.
• Placebo Group: 26 of 145 patients (17.9%) achieved the primary endpoint.

The observed difference between groups was 17.2% (95% confidence interval: 6.8% to 27.2%). Adjusted analysis further demonstrated an odds ratio of 2.49 (95% confidence interval: 1.42 to 4.36) for achieving SOFA improvement by day 9 in the precision immunotherapy group, underscoring the treatment's positive effect.

Favorable Secondary Outcomes

Beyond the primary endpoint, several secondary outcomes also favored precision immunotherapy, reinforcing the observed benefits:

• SOFA score improvement by day 15: 39.7% in the immunotherapy group vs. 23.4% in the placebo group.
• Reversal of sepsis-induced immune dysfunction: 78.0% in the immunotherapy group vs. 48.5% in the placebo group.
• Infection resolution by day 15: 44.3% in the immunotherapy group vs. 31.7% in the placebo group.

Mortality and Safety Profile

Mortality outcomes at 28 and 90 days were not statistically different between the groups.

A total of 1069 serious treatment-emergent adverse events were reported in 245 patients (88.8%). Of these, 13 serious adverse reactions were considered probably or possibly related to the study drug. An increased incidence of anemia was noted in the anakinra group, and hemorrhage in the recombinant human interferon gamma group. Overall, no major safety concerns were reported, indicating a manageable safety profile.

Implications for Personalized Sepsis Treatment

The findings highlight the potential of precision medicine in critical care, suggesting that tailoring treatment based on individual immune profiles can improve organ dysfunction in sepsis.

While these results mark a significant step, it is important to note that the primary endpoint was a surrogate outcome. Therefore, further research is needed to evaluate patient-centered outcomes, particularly long-term survival.

Additionally, the availability of the required specialized laboratory testing for immune profiling may pose a limiting factor for widespread implementation. Nonetheless, the ImmunoSep study's results indicate a significant stride toward developing more personalized and effective sepsis treatment strategies.